Trials / Completed

CompletedNCT05014815

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 272 (actual)

Sponsor: BeiGene · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Conditions

Interventions

Type	Name	Description
DRUG	Ociperlimab	900 mg intravenously (IV) once every 3 weeks (Q3W)
DRUG	Tislelizumab	200 mg IV Q3W
DRUG	Carboplatin	Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
DRUG	Paclitaxel	75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
DRUG	Nab paclitaxel	100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
DRUG	Cisplatin	75 mg/m², administered intravenously on Day 1 of each 21-day cycle
DRUG	Pemetrexed	500 mg/m² administered intravenously on Day 1 of each 21-day cycle
DRUG	Placebo	Administered intravenously Q3W to match ociperlimab

Timeline

Start date: 2021-11-16
Primary completion: 2024-09-04
Completion: 2024-09-04
First posted: 2021-08-20
Last updated: 2025-09-16
Results posted: 2025-09-16

Locations

64 sites across 8 countries: United States, Australia, Austria, China, France, Greece, South Korea, Spain

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05014815. Inclusion in this directory is not an endorsement.